Promising cancer drug study halted early: what happened?
NCT ID NCT06478862
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific genetic changes (BRCA or HRD mutations) and had stopped responding to first treatment. The goal was to see if Promitil could slow or stop cancer growth. The study was ended early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rambam Health Care Campus
Haifa, Israel
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Shamir Medical Center (Asaf Harofeh)
Ẕerifin, 70300, Israel
-
Soroka Medical Center
Beersheba, Israel
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Wolfson Medica Center
Holon, 5822012, Israel
Conditions
Explore the condition pages connected to this study.